Alexandria
VC Fund
San Francisco, United States
Alexandria is a VC fund in San Francisco focused on Biotechnology and Health Care. Alexandria Venture Investments is a strategic venture capital arm of Alexandria Real Estate Equities. Alexandria Venture Investments provides long-term strategic investment capital to innovative life science and technology entities developing breakthrough technologies and therapies. Leveraging their experience and in-depth understanding of thelife science and technology industries, their long-term relationships with leading investors, and their world-class scientific advisory network, they are uniquely positioned to fund seed-, early-, and growth-stage companies.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 3%
Last updated:
For AI agents: llms.txt
Industries Alexandria invests in
Stages Alexandria invests in
Countries Alexandria invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Biotechnology 27 (84%)
- Health Care 17 (53%)
- Therapeutics 13 (41%)
- Medical 6 (19%)
- Biopharma 5 (16%)
Stage
- Series A 14 (44%)
- Series B 7 (22%)
- Series C 4 (13%)
- Seed 3 (9%)
- Private Equity 1 (3%)
Country
- United States 28 (88%)
- Canada 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dean A. Shigenaga
Co-President & Chief Financial Officer
|
Co-President & Chief Financial Officer | Total investments: 0 | Find email | |
Joel Marcus
Founder
|
Founder | Total investments: 8 | Find email | |
Peter M. Moglia
Co-Chief Executive Officer & Co-Chief Investment Officer
|
Co-Chief Executive Officer & Co-Chief Investment Officer | Total investments: 0 | Find email | |
Stephen A. Richardson
Co-Chief Executive Officer
|
Co-Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M / Venture - Series Unknown / Sep 04, 2025 | |
Radiant Biotherapeutics
|
Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $8M / Seed / Apr 25, 2023 | |
Tiamat Sciences
|
Tiamat is a start-up producing affordable animal-free growth factors and biomolecules using plants as bioreactors. Thanks to its propriety platform, the company can manufacture a wide range of high-value proteins from antigens to growth factors.The company has already achieved a 10x cost reduction and at scale can get costs down 1000x even at 80%growth-margins, giving them a wide ability to price strategically. the coming years. The low investment needed to build a facility (up to 40x less than current solutions) combined with its unique technology makes Tiamat the ideal partner in production scale-up for promising markets that will soon become enormous such as cellular agriculture or cell & gene therapy. | $2M / Seed / Mar 09, 2023 | |
BIOMILQ
|
BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact inearly-life nutrition with ingredients that promote immune, gut, and neurological development. | $21M / Series A / Oct 20, 2021 | |
Kojin Therapeutics
|
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases.The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital. | $60M / Series A / Jun 09, 2021 | |
Think Brilliant Media Studios
|
Think Brilliant Media Studios specializes in high performance web development and custom media solutions across multiple platforms. | $7M / Private Equity / Aug 13, 2020 | |
TARA Biosystems
|
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiacfunctionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines. | $10M / Series A / Jun 23, 2020 | |
Crop Enhancement
|
Crop Enhancement develop a new approach that will help farmers increase crop yields and profitability in a sustainable way. By developing agrochemical formulations that employ advanced and environmentally friendly chemistry, we help improve crop yields, eliminate or minimize pesticide use, and enable precise and effective delivery of activeingredients and fertilizers. | $8M / Series B / Apr 14, 2020 | |
Triplet Therapeutics
|
Triplet is developing transformative therapies that treat repeat expansion disorders at their source. | $49M / Series A / Dec 17, 2019 | |
Immunitas Therapeutics
|
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $39M / Series A / Nov 21, 2019 | |
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexandria invest in?
Alexandria invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexandria?
Public channels for Alexandria include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alexandria?
The team at Alexandria includes Dean A. Shigenaga (Co-President & Chief Financial Officer), Joel Marcus (Founder) and Peter M. Moglia (Co-Chief Executive Officer & Co-Chief Investment Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
